PolyBio

PolyBio’s inaugural Convergence Summit 2026 is fast approaching! From November 18 to 20, presentations will address evolving research on the relationship between pathogens and chronic diseases such as Long COVID, chronic Lyme disease, MS, Alzheimer’s, and more. The meeting will bring together leading researchers, clinicians, biotech innovators and public health experts to address the rapid need for IACI diagnostics and treatments to translate from the lab bench to hospital bedside.

We’re pleased to announce the inaugural PolyBio Convergence Summit will take place this November 18 to 20. Presentations will explore the latest advances in persistent infections and their emerging roles in conditions such as Long COVID, chronic Lyme disease, multiple sclerosis, Alzheimer’s, and aging. Discussions will focus on the practical challenges that must be addressed to translate these discoveries into validated diagnostics, clinical trials, and effective therapies. Add the virtual schedule to your calendar here: calendar.google.com/calendar…

Actively recruiting: Extended decentralized trial of a novel therapeutic device to reduce chronic pain in post-treatment Lyme disease 👉🏻Eligibility criteria below The Sana Pain Reliever is a frequency-based therapeutic device that has been shown to reduce all-cause neuropathic pain. 1/

At the Harvard/MIT Martinos Center, Dr. Mario Murakami and the VanElzakker lab are using ultrahigh-resolution 7T fMRI to understand how changes to cerebrospinal fluid (CSF) flow in people with Craniocervical Instability can produce a phenotype similar to that seen in ME/CFS and other neuroimmune conditions. The brain relies on cerebrospinal fluid to carry out metabolic waste that builds up during normal physiological processes, acting as a “garbage disposal,” as explained by Murakami. Changes to healthy CSF flow may result in the buildup of these metabolites in the brain. Said Murakami, “There is a compromised structure of CSF flow in CCI [patients] compared with healthy controls, which means that maybe this is part of the mechanisms which drive the symptoms—the brain fog, the pain, the fatigue, the autonomic dysfunction.”

3/ This study builds on growing evidence that a portion of patients with IACI, including Long COVID and ME/CFS, possess functional and structural brainstem abnormalities. The brainstem itself is additionally susceptible to CSF flow changes, and contains dorsal nuclei that control autonomic function, pain, sleep, and sickness behavior—which, if dysfunctional, could have implications for these functions.